Equities analysts predict that Aptevo Therapeutics Inc (NASDAQ:APVO) will announce earnings of ($0.59) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aptevo Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.58) and the lowest estimate coming in at ($0.60). Aptevo Therapeutics reported earnings of $0.14 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 521.4%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 8th.

According to Zacks, analysts expect that Aptevo Therapeutics will report full year earnings of ($2.42) per share for the current year, with EPS estimates ranging from ($2.47) to ($2.36). For the next year, analysts expect that the firm will report earnings of ($2.35) per share, with EPS estimates ranging from ($2.68) to ($2.02). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVO) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.07. Aptevo Therapeutics had a net margin of 74.01% and a negative return on equity of 45.53%. The business had revenue of $6.83 million during the quarter, compared to analysts’ expectations of $4.17 million.

A number of research analysts have commented on the stock. ValuEngine upgraded shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Zacks Investment Research lowered shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $11.00 price objective on shares of Aptevo Therapeutics in a report on Friday, August 10th.

Shares of NASDAQ APVO traded up $0.09 during mid-day trading on Friday, hitting $5.12. The company had a trading volume of 200 shares, compared to its average volume of 82,538. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.50 and a current ratio of 3.66. Aptevo Therapeutics has a 12 month low of $1.78 and a 12 month high of $6.35. The stock has a market cap of $115.61 million, a PE ratio of -3.31 and a beta of 0.68.

Several hedge funds and other institutional investors have recently bought and sold shares of APVO. EAM Investors LLC acquired a new stake in shares of Aptevo Therapeutics in the second quarter valued at approximately $552,000. Spark Investment Management LLC increased its holdings in shares of Aptevo Therapeutics by 82.8% in the first quarter. Spark Investment Management LLC now owns 129,400 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 58,600 shares in the last quarter. Alambic Investment Management L.P. acquired a new stake in shares of Aptevo Therapeutics in the first quarter valued at approximately $646,000. Victory Capital Management Inc. increased its holdings in shares of Aptevo Therapeutics by 10.3% in the first quarter. Victory Capital Management Inc. now owns 215,110 shares of the biotechnology company’s stock valued at $703,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Aptevo Therapeutics by 11.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,219,852 shares of the biotechnology company’s stock valued at $3,989,000 after purchasing an additional 123,236 shares in the last quarter. 33.08% of the stock is owned by institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Featured Story: What do I need to know about analyst ratings?

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.